Conference Coverage
Conference Coverage
Stereotactic radiotherapy cost effective for early NSCLC
Major finding: A cost-analysis model showed that for patients older than 65 with marginally operable stage I non–small cell lung tumors,...
Conference Coverage
Most data reassure regarding TNF inhibitors and cancer
Conference Coverage
For neoadjuvant androgen suppression in prostate cancer, 8 is enough
Major finding: Ten-year disease-specific survival rates for men with intermediate risk prostate cancer were 95% for those who received 8 weeks of...
Conference Coverage
Tumor distance from nipple boosts nomogram results
Major finding: Positive sentinel nodes were seen in 17 of 33 (52%) tumors within 2 cm of the nipple, compared with 17% of 368 tumors more than 2...
Conference Coverage
ASTRO outlines five radiation oncology practices that should be curtailed
Conference Coverage
Breast cancer receptor change may predict outcomes
Major finding: Receptor status changed in 41% of breast cancers after neoadjuvant chemotherapy.
Conference Coverage
Racial disparities found in thyroid cancer care
Major finding: Nonwhite patients with thyroid cancer were 36%-89% more likely to present with metastatic disease, compared with whites.Data source...
Conference Coverage
Prolaris test eyed as predictor of prostate cancer outcomes
Major finding: In conservatively managed prostate cancer patients, the cell cycle progression score in tissue samples was the dominant variable...
Conference Coverage
No survival benefit for routine surveillance scans in classical Hodgkin disease
Major finding: The ratio of scans to detected relapses was 18 for the clinical surveillance group and 124 for the routine scan group.
Conference Coverage
In esophageal cancer, adenocarcinoma rates increased over four decades
Major finding: During the past 40 years, overall median survival for esophageal cancer significantly increased, from 6 months to 10 months (P less...
Conference Coverage
Simple conditioning, GVHD prophylaxis yields good hematologic malignancy survival
Major finding: For patients with hematologic malignancies treated with busulfan/fludarabine conditioning, allogeneic bone marrow transplant, and...